CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis

IntroductionHuman cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive therapy as the primary standard of care for H...

Full description

Bibliographic Details
Main Authors:	Chris David Lauruschkat, Ihsan Muchsin, Alice Rein, Florian Erhard, Denise Grathwohl, Lars Dölken, Carolin Köchel, Christine Susanne Falk, Hermann Einsele, Sebastian Wurster, Götz Ulrich Grigoleit, Sabrina Kraus
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	human cytomegalovirus (HCMV) viral infection allogeneic stem cell transplantation T cells NK cells
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1148841/full

Similar Items

Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report
by: Stefania Paolucci, et al.
Published: (2021-09-01)

Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients
by: Colombo Anna, et al.
Published: (2012-10-01)

Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation
by: Katrin Lazar, et al.
Published: (2021-09-01)

Frequencies of activated T cell populations increase in breast milk of HCMV-seropositive mothers during local HCMV reactivation
by: Katrin Lazar, et al.
Published: (2024-01-01)

The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts
by: Masatoshi Nukui, et al.
Published: (2018-11-01)

Persistent CD8 T Cell Marks Caused by the HCMV Infection in Seropositive Adults: Prevalence of HLA-E-Reactive CD8 T Cells
by: Amélie Rousselière, et al.
Published: (2023-03-01)

Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients
by: M. Bahador, et al.
Published: (2017-08-01)

Biology and Clinical Relevance of HCMV-Associated Adaptive NK Cells
by: Fei Gao, et al.
Published: (2022-03-01)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
by: Susanne Jung, et al.
Published: (2019-05-01)

Impact of HCMV infection on NK cell development and function after HSCT
by: Mariella eDella Chiesa, et al.
Published: (2013-12-01)

Indeterminate/moderate IgG avidity during HCMV infection: comparison of methods
by: Massimo De Paschale, et al.
Published: (2010-03-01)

Spanish HCMV Seroprevalence in the 21st Century
by: Pablo Álvarez-Heredia, et al.
Published: (2023-12-01)

Association of human cytomegalovirus (HCMV) neutralizing antibodies with antibodies to the HCMV glycoprotein complexes
by: Miho Shibamura, et al.
Published: (2020-08-01)

Suppressive effects of pterostilbene on human cytomegalovirus (HCMV) infection and HCMV-induced cellular senescence
by: Sanying Wang, et al.
Published: (2022-12-01)

CARs—A New Perspective to HCMV Treatment
by: Christopher Bednar, et al.
Published: (2021-08-01)

The Reactivity of Anti-HCMV IgM to Various Specific HCMV Antigens Among Pregnant Women in Kirkuk.
by: Staar Qader, et al.
Published: (2018-12-01)

The Role of RhoA, RhoB and RhoC GTPases in Cell Morphology, Proliferation and Migration in Human Cytomegalovirus (HCMV) Infected Glioblastoma Cells
by: Melpomeni Tseliou, et al.
Published: (2016-01-01)

IL-10-Secreting CD8<sup>+</sup> T Cells Specific for Human Cytomegalovirus (HCMV): Generation, Maintenance and Phenotype
by: Sarah E. Jackson, et al.
Published: (2022-12-01)

Productive Infection of Human Breast Cancer Cell Lines with Human Cytomegalovirus (HCMV)
by: Kaitlin M. Branch, et al.
Published: (2021-05-01)

Changes in HCMV immune cell frequency and phenotype are associated with chronic lung allograft dysfunction
by: Amélie Rousselière, et al.
Published: (2023-04-01)

Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience
by: Massimo Martino, et al.
Published: (2021-09-01)

Characterization of the HCMV-Specific CD4 T Cell Responses that Are Associated with Protective Immunity
by: Marie Wunsch, et al.
Published: (2015-08-01)

Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells
by: Sebastian J. Theobald, et al.
Published: (2018-11-01)

Autologous T-Cell-Free Antigen Presentation System Unveils hCMV-Specific NK Cell Response
by: Maria O. Ustiuzhanina, et al.
Published: (2024-03-01)

Characterization of Human Cytomegalovirus (HCMV) Long Non-Coding RNA1.2 During Lytic Replication
by: Salomé Manska, et al.
Published: (2025-01-01)

HCMV-IE2 promotes atherosclerosis by inhibiting vascular smooth muscle cells’ pyroptosis
by: Guixin Ma, et al.
Published: (2023-05-01)

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study
by: Léna Royston, et al.
Published: (2021-04-01)

Evaluation of an in-house specific immunoglobulin G (IgG) avidity ELISA for distinguishing recent primary from long-term human cytomegalovirus (HCMV) infection
by: Silmara de Souza, et al.
Published: (2003-12-01)

Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience
by: Jessica Gill, et al.
Published: (2023-04-01)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
by: Dukhee Nho, et al.
Published: (2023-09-01)

Broad and Efficient Activation of Memory CD4+ T Cells by Novel HAdV- and HCMV-Derived Peptide Pools
by: Alexander Höttler, et al.
Published: (2021-07-01)

Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis
by: Martyna Wlodarczyk, et al.
Published: (2024-03-01)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
by: Restelli U, et al.
Published: (2019-05-01)

Seroprevalence of HCMV among Pregnant Women and Its relation to CD4 and CRP
by: Staar Mohammed Qader
Published: (2018-09-01)

Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study
by: Yuling Zhang, et al.
Published: (2024-01-01)

HCMV carriage in the elderly diminishes anti-viral functionality of the adaptive immune response resulting in virus replication at peripheral sites
by: Emma L. Davies, et al.
Published: (2022-12-01)

Comparative analyses of DNA extraction methods for whole blood quantification of HCMV DNAemia in patients with hematological diseases: false negative cases in manual method
by: Gabriella Bianchino, et al.
Published: (2023-08-01)

Secretion of IFN-γ by specific T cells in HCMV infection
by: Hanying Liang, et al.
Published: (2024-03-01)

The Role of HCMV and HIV-1 MicroRNAs: Processing, and Mechanisms of Action during Viral Infection
by: Doriana Fruci, et al.
Published: (2017-04-01)

HCMV detection in Asian gastric cancer RNA-seq data sets and clinical validation in Indian GC patients reveals the HCMV-GC specific gene signatures
by: Pandikannan Krishnamoorthy, et al.
Published: (2024-10-01)